The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.
Management of chronic myeloid leukemia in 2023 – common ground and common sense
Open accessAbstract
With the improving knowledge of CML and its management, the goals of therapy need to be revisited to ensure an optimal use of the BCR::ABL1 TKIs in the frontline and later-line therapy of CML. In the frontline therapy of CML in the chronic phase (CML-CP), imatinib and the three second-generation TKIs (bosutinib, dasatinib and nilotinib) are associated with comparable survival results. The second-generation TKIs may produce earlier deep molecular responses, hence reducing the time to reaching a treatment-free remission (TFR). The choice of the second-generation TKI versus imatinib in frontline therapy is based on the treatment aims (survival, TFR), the CML risk, the drug cost, and the toxicity profile with respect to the patient’s comorbidities. The TKI dosing is more flexible than has been described in the registration trials, and dose adjustments can be considered both in the frontline and later-line settings (e.g., dasatinib 50 mg frontline therapy; dose adjusted schedules of bosutinib and ponatinib), as well as during an ongoing TKI therapy to manage toxicities, before considering changing the TKI. In patients who are not candidates for TFR, BCR::ABL1 (International Scale) transcripts levels <1% are acceptable, result in virtually similar survival as with deeper molecular remissions, and need not warrant a change of TKI. For patients with true resistance to second-generation TKIs or with the T315I gatekeeper mutation, the third-generation TKIs are preferred. Ponatinib should be considered first because of the cumulative experience and results in the CML subsets, including in T315I-mutated CML. A response-based dosing of ponatinib is safe and leads to high TKI compliance. Asciminib is a third-generation TKI with possibly a better toxicity profile, but lesser activity in T315I-mutated CML. Olverembatinib is another potent third-generation TKI with early promising results.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia
Hochhaus, A., Baccarani, M., Silver, R. T., Schiffer, C., Apperley, J. F., Cervantes, F., Clark, R. E., Cortes, J. E., Deininger, M. W., Guilhot, F., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0776-2 · Cited by 1,547 · cited 1×
“HOW IMPORTANT IS IT TO ACHIEVE THE LANDMARK OPTIMAL RESPONSES RECOMMENDED BY THE ELN AND NCCN? The ELN recommendations and NCCN guidelines highlight the importance of achieving an “early molecular response” (EMR; defined as BCR::ABL1 transcripts [IS] < 10% at 3–6 months) and a complete cytogenetic response (CCyR; appr…”
BackgroundSelf-citationBower, H., Björkholm, M., Dickman, P. W., Höglund, M., Lambert, P. C., & Andersson, T. M.-L. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.66.2866 · Cited by 904
Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias
Cortes, J. E., Kantarjian, H., Shah, N. P., Bixby, D., Mauro, M. J., Flinn, I., O'Hare, T., Hu, S., Narasimhan, N. I., Rivera, V. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205127 · Cited by 769
Self-citationKantarjian, H. M., Hughes, T. P., Larson, R. A., Kim, D.-W., Issaragrisil, S., le Coutre, P., Etienne, G., Boquimpani, C., Pasquini, R., Clark, R. E., et al. (2021) · Leukemia · doi:10.1038/s41375-020-01111-2 · Cited by 351
Self-citationCortes, J., Apperley, J., Lomaia, E., Moiraghi, B., Undurraga Sutton, M., Pavlovsky, C., Chuah, C., Sacha, T., Lipton, J. H., Schiffer, C. A., et al. (2021) · Blood · doi:10.1182/blood.2021012082 · Cited by 208
Self-citationClark, R. E., Polydoros, F., Apperley, J. F., Milojkovic, D., Rothwell, K., Pocock, C., Byrne, J., de Lavallade, H., Osborne, W., Robinson, L., et al. (2019) · The Lancet Haematology · doi:10.1016/s2352-3026(19)30094-8 · Cited by 195
Optimal Dosing for Targeted Therapies in Oncology: Drug Development Cases Leading by Example
Sachs, J. R., Mayawala, K., Gadamsetty, S., Kang, S. P., & de Alwis, D. P. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1295 · Cited by 159 · cited 1×
“Originally, the TKIs (and many of the novel recent targeted therapies) were developed in strategies similar to the ones used for chemotherapy, at one dose lower than the maximum tolerated dose (MTD), which was based on the first 1-2 courses of therapy [73].”
MethodNaqvi, K., Jabbour, E., Skinner, J., Anderson, K., Dellasala, S., Yilmaz, M., Ferrajoli, A., Bose, P., Thompson, P., Alvarado, Y., et al. (2020) · Cancer · doi:10.1002/cncr.32504 · Cited by 135
Self-citationJiang, Q., Li, Z., Qin, Y., Li, W., Xu, N., Liu, B., Zhang, Y., Meng, L., Zhu, H., Du, X., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01334-z · Cited by 102
Pfirrmann, M., Clark, R. E., Prejzner, W., Lauseker, M., Baccarani, M., Saussele, S., Guilhot, F., Heibl, S., Hehlmann, R., Faber, E., et al. (2020) · Leukemia · doi:10.1038/s41375-020-0931-9 · Cited by 96
Cited by
Cancer treatments: Past, present, and future
Sonkin, D., Thomas, A., & Teicher, B. A. (2024) · Cancer Genetics · doi:10.1016/j.cancergen.2024.06.002 · Cited by 548
Asciminib in Newly Diagnosed Chronic Myeloid Leukemia
Hochhaus, A., Wang, J., Kim, D.-W., Kim, D. D. H., Mayer, J., Goh, Y.-T., le Coutre, P., Takahashi, N., Kim, I., Etienne, G., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2400858 · Cited by 171
Self-citationCortes, J. E., Lang, F., Rea, D., Hochhaus, A., Breccia, M., Goh, Y. T., Heinrich, M. C., Hughes, T. P., Janssen, J. J. W. M., le Coutre, P., et al. (2025) · Leukemia · doi:10.1038/s41375-025-02592-9 · Cited by 16
Self-citationChen, E. Y., Dahlén, T., Stenke, L., Björkholm, M., Hao, S., Dickman, P. W., & Clements, M. S. (2025) · European Journal of Haematology · doi:10.1111/ejh.14328 · Cited by 13
Kantarjian, H., Zhai, Y., Oehler, V. G., Jamy, O., Koller, P. B., Haddad, F. G., Sasaki, K., & Jabbour, E. J. (2025) · Cancer · doi:10.1002/cncr.35832 · Cited by 10
“5,13 On the other hand, certain side effects warrant alternative treatment strategies beyond dose reductions: recurrent pleural effusions or pulmonary hypertension (e.g., with dasatinib); arterial occlusive events (AOEs; e.g., ponatinib and nilo-tinib); enterocolitis (e.g., bosutinib);…”
Self-citation
Metadata
- Authors
- Senapati, J., Sasaki, K., Issa, G. C., Lipton, J. H., Radich, J. P., Jabbour, E., & Kantarjian, H. M.
- Venue
- Blood Cancer Journal
- Published
- 2023-04-24
- Volume
- 13
- Issue
- 1
- Pages
- 58-58
- ISSN
- 2044-5385 (ISSN-L)
- OpenAlex
- W4366822278
- Cited by
- 176
- References
- 15
- FWCI
- 31.36
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Management of chronic myeloid leukemia in 2023 – common ground and common sense. https://app.cochat.ai/papers/10.1038/s41408-023-00823-9
- The paper
- Senapati, J., Sasaki, K., Issa, G. C., Lipton, J. H., Radich, J. P., Jabbour, E., & Kantarjian, H. M. (2023). Management of chronic myeloid leukemia in 2023 – common ground and common sense. Blood Cancer Journal. https://doi.org/10.1038/s41408-023-00823-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.